Inozyme CEO Disposes All Shares in BioMarin Acquisition – Form 4 Details
Rhea-AI Filing Summary
Inozyme Pharma, Inc. (INZY) — Insider Form 4 Overview
CEO & Chairman Douglas A. Treco filed a Form 4 detailing the automatic disposition of his entire equity stake following the closing of Inozyme’s merger with BioMarin Pharmaceutical Inc. on 1 July 2025. Under the Agreement and Plan of Merger dated 16 May 2025, BioMarin’s wholly owned Incline Merger Sub acquired all outstanding Inozyme shares for $4.00 cash per share.
- Common stock: 43,861 shares were tendered at $4.00, eliminating Treco’s direct share ownership.
- Restricted stock units: 150,000 RSUs automatically accelerated, vested, and converted to a $4.00 cash payout per underlying share.
- Stock options: 86,979 options (exercise $2.77) and 400,000 options (exercise $1.06) vested and were cancelled in exchange for the cash spread between the $4.00 consideration and each strike price.
Following the transactions, Treco reports zero remaining beneficial ownership, reflecting Inozyme’s status as a wholly owned BioMarin subsidiary. The filing is largely procedural, confirming final insider settlement terms aligned with the previously announced merger.
Positive
- None.
Negative
- None.
Insights
TL;DR: Filing confirms final insider cash-out as BioMarin completes Inozyme takeover; no residual equity remains.
This Form 4 is a standard post-closing disclosure. All equity instruments—common, RSUs, and in-the-money options—were settled for cash under the $4.00 tender price. The option spread delivers modest incremental value (≈$1.23 and $2.94 per share for the two tranches), but materially the event only reiterates that the merger closed on 1 July 2025 and insiders no longer hold Inozyme stock. Because the deal terms were publicly known since May, the filing has minimal incremental information value for investors and no direct market impact on either BioMarin or any remaining Inozyme securities (which will be delisted).
TL;DR: Routine insider disposition; cash settlement aligns with previously fixed $4.00 exit price.
For portfolio holders, this disclosure merely documents execution mechanics: common holders receive $4.00; option holders capture intrinsic value. There is no change to payout, timing, or tax treatment beyond what the merger proxy outlined. The lack of residual equity confirms the completion of the transaction and removes Inozyme from investable universes. Consequently, the filing is administrative rather than a driver of valuation or trading strategy.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Restricted Stock Units | 150,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 86,979 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 400,000 | $0.00 | -- |
| U | Common Stock | 43,861 | $4.00 | $175K |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
